5-(2-(4-morpholinophenyl)hydrazono)dihydro-2-thioxopyrimidine-4,6(1H,5H)-dione | 1401785-14-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 恶嗪烷类
• 英文名称: 5-(2-(4-morpholinophenyl)hydrazono)dihydro-2-thioxopyrimidine-4,6(1H,5H)-dione
• 英文别名: 5-[(4-morpholin-4-ylphenyl)hydrazinylidene]-2-sulfanylidene-1,3-diazinane-4,6-dione
• CAS: 1401785-14-5
• 化学式: C₁₄H₁₅N₅O₃S
• 分子量: 333.371
• InChiKey: MDZQPRHNZQFNEJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.18
• 重原子数：
  23.0
• 可旋转键数：
  3.0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  95.06
• 氢给体数：
  3.0
• 氢受体数：
  7.0

反应信息

• 作为产物：
  描述：

  4,6-二羟基-2-巯基嘧啶 、 4-(4-吗啉基)苯胺 在 盐酸 、 sodium nitrite 、 sodium acetate 作用下， 以 水 、 乙醇 为溶剂， 生成 5-(2-(4-morpholinophenyl)hydrazono)dihydro-2-thioxopyrimidine-4,6(1H,5H)-dione
  参考文献：
  名称：

  Synthesis, activity evaluation, and docking analysis of barbituric acid aryl hydrazone derivatives as RSK2 inhibitors

  摘要：

  The 90 kDa ribosomal S6 kinases (RSKs), especially RSK2, have attracted attention for the development of new anticancer agents. Through structural optimization of the hit compound 1 from our previous study, a series of barbituric acid aryl hydrazone analogues were designed and synthesized as potential RSK2 inhibitors. The most potent one, compound 9, showed a higher activity against RSK2 with an IC50 value of 1.95 mu M. To analyze and elucidate their structure-activity relationship, the homology model of RSK2 N-terminal kinase domain was built and molecular docking simulations were performed, which provide helpful clues to design new inhibitors with desired activities.

  DOI：

  10.3109/14756366.2012.681651

文献信息

• Synthesis, activity evaluation, and docking analysis of barbituric acid aryl hydrazone derivatives as RSK2 inhibitors
  作者：Mengzhu Xue、Minghao Xu、Weiqiang Lu、Jin Huang、Honglin Li、Yufang Xu、Xiaofeng Liu、Zhenjiang Zhao

  DOI：10.3109/14756366.2012.681651

  日期：2013.8.1

  The 90 kDa ribosomal S6 kinases (RSKs), especially RSK2, have attracted attention for the development of new anticancer agents. Through structural optimization of the hit compound 1 from our previous study, a series of barbituric acid aryl hydrazone analogues were designed and synthesized as potential RSK2 inhibitors. The most potent one, compound 9, showed a higher activity against RSK2 with an IC50 value of 1.95 mu M. To analyze and elucidate their structure-activity relationship, the homology model of RSK2 N-terminal kinase domain was built and molecular docking simulations were performed, which provide helpful clues to design new inhibitors with desired activities.